Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DETROL

« Back to Dashboard
Detrol is a drug marketed by Pharmacia And Upjohn and is included in two NDAs. It is available from four suppliers. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in DETROL is tolterodine tartrate. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the tolterodine tartrate profile page.

Summary for Tradename: DETROL

Suppliers / Packagers: see list17

Pharmacology for Tradename: DETROL

Clinical Trials for: DETROL

A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Active, not recruiting Condition: Overactive Bladder (OAB)

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Status: Completed Condition: Overactive Bladder

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Status: Completed Condition: Benign Prostatic Hyperplasia (BPH)

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
Status: Terminated Condition: Urinary Incontinence

Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Status: Completed Condition: Overactive Bladder

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Status: Completed Condition: Pharmacokinetics of Mirabegron and Tolterodine; Healthy

A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2])
Status: Completed Condition: Urinary Bladder, Overactive

Pharmacokinetics and Relative Bioavailability Study
Status: Completed Condition: Urinary Bladder, Overactive

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
tolterodine tartrate
TABLET;ORAL020771-001Mar 25, 1998RXNo<disabled><disabled>
Pharmacia And Upjohn
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 2000RXYes6,770,295*PED<disabled>Y<disabled>
Pharmacia And Upjohn
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000RXNo6,770,295*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DETROL

Drugname Dosage Strength RLD Submissiondate
tolterodine tartrateTablets1 mg and 2 mgDetrol
tolterodine tartrateExtended-release Capsules2 mg and 4 mgDetrol LA7/30/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn